Effects on Blood Neurodegeneration Biomarkers of a Randomized Hearing Rehabilitation Intervention

Abstract The Aging and Cognitive Health Evaluation in Elders (ACHIEVE) study is a multicenter, parallel-arm, randomized trial (hearing intervention vs health education control) on 3-year cognitive decline among adults 70–84years with untreated hearing loss and without substantial cognitive impairment. Participants were recruited from: (1)a long-standing observational study (Atherosclerosis Risk in Communities [ARIC]), and (2)de novo community volunteers. In ACHIEVE, intervention slowed 3-year cognitive decline by 48% among ARIC participants only. To further investigate differences by treatment with respect to cognitive benefit, we tested the hypothesis that hearing intervention is associated with improved neurodegeneration blood biomarkers 3-years post-randomization. Plasma was collected in year 3 in a subsample (n = 540) while ARIC participants (n = 164) also had baseline plasma. Glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) neurodegenerative biomarkers were derived using the Alamar CNS protein panel. Regression models estimated the association of treatment with 3-year biomarkers differences in the combined sample and by recruitment source and annualized change from baseline in the ARIC sample. Baseline characteristics were balanced by treatment. There were no significant differences on 3-year neurodegeneration biomarker levels by treatment in the combined or de novo groups. Among ARIC participants, intervention resulted in lower 3-year GFAP(mean:-0.415;95%CI:-0.712,-0.118) and NfL(mean:-0.349;95%CI:-0.652,-0.046). Annualized change from baseline analyses among ARIC participants revealed intervention was associated with a slower rate of increase in GFAP (difference-in-means: -0.060;95%CI:-0.112,-0.009). Hearing intervention was associated with positive 3-year effects on neurodegeneration blood biomarkers in ARIC participants which parallels cognitive decline results. Results provides objective evidence of brain changes following hearing intervention.

Authors

Institutions

Publication Details

Journal
Innovation in Aging
Published
2025-12-01
DOI
https://doi.org/10.1093/geroni/igaf122.1081
Primary Topic
Hearing Loss and Rehabilitation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effects on Blood Neurodegeneration Biomarkers of a Randomized Hearing Rehabilitation Intervention

Jennifer A. Deal, James Russell Pike, Nicholas Reed, Priya Palta et al.
Innovation in Aging
Hearing Loss and Rehabilitation
article

Effects on Blood Neurodegeneration Biomarkers of a Randomized Hearing Rehabilitation Intervention

Jennifer A. Deal, James Russell Pike, Nicholas Reed, Priya Palta, Josef Coresh
article en

Abstract

Abstract The Aging and Cognitive Health Evaluation in Elders (ACHIEVE) study is a multicenter, parallel-arm, randomized trial (hearing intervention vs health education control) on 3-year cognitive decline among adults 70–84years with untreated hearing loss and without substantial cognitive impairment. Participants were recruited from: (1)a long-standing observational study (Atherosclerosis Risk in Communities [ARIC]), and (2)de novo community volunteers. In ACHIEVE, intervention slowed 3-year cognitive decline by 48% among ARIC participants only. To further investigate differences by treatment with respect to cognitive benefit, we tested the hypothesis that hearing intervention is associated with improved neurodegeneration blood biomarkers 3-years post-randomization. Plasma was collected in year 3 in a subsample (n = 540) while ARIC participants (n = 164) also had baseline plasma. Glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) neurodegenerative biomarkers were derived using the Alamar CNS protein panel. Regression models estimated the association of treatment with 3-year biomarkers differences in the combined sample and by recruitment source and annualized change from baseline in the ARIC sample. Baseline characteristics were balanced by treatment. There were no significant differences on 3-year neurodegeneration biomarker levels by treatment in the combined or de novo groups. Among ARIC participants, intervention resulted in lower 3-year GFAP(mean:-0.415;95%CI:-0.712,-0.118) and NfL(mean:-0.349;95%CI:-0.652,-0.046). Annualized change from baseline analyses among ARIC participants revealed intervention was associated with a slower rate of increase in GFAP (difference-in-means: -0.060;95%CI:-0.112,-0.009). Hearing intervention was associated with positive 3-year effects on neurodegeneration blood biomarkers in ARIC participants which parallels cognitive decline results. Results provides objective evidence of brain changes following hearing intervention.

Innovation in AgingVol. 9(Supplement_2)
Johns Hopkins University (US), UNC/NCSU Joint Department of Biomedical Engineering (US), New York University (US)
Quality Education
Openalex Percentile: Top 30%
Hearing Loss and Rehabilitation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.